Results 141 to 150 of about 1,040,935 (315)

Screening and epitope characterization of Nidogen‐2‐specific nanobodies

open access: yesFEBS Open Bio, EarlyView.
Camel immunization and phage display were employed to generate high‐affinity VHH nanobodies against Nidogen‐2. After library construction, biopanning, ELISA screening, sequencing, and recombinant expression, selected nanobodies were purified and characterized, leading to the preliminary exploration of a nanobody‐based sandwich ELISA for specific ...
Jianchuan Wen   +9 more
wiley   +1 more source

Biomarkers in cancer [PDF]

open access: yesClinical Chemistry and Laboratory Medicine (CCLM), 2021
openaire   +2 more sources

MiR‐513a promotes human erythroid differentiation by modulating c‐Jun

open access: yesFEBS Open Bio, EarlyView.
During early human erythropoiesis, miR‐513a promoted erythroid differentiation in primary human CD34+ hematopoietic stem‐progenitor cells and human TF‐1 erythroleukemic cells by indirectly decreasing c‐Jun and phospho‐c‐Jun expression, which are associated with increased GATA1 expression.
MinJung Kim   +11 more
wiley   +1 more source

Clot time ratio (CTR) and relation to treatment outcome in patients with atrial fibrillation treated with Rivaroxaban

open access: yesThrombosis Journal
Background There are situations where information about the anticoagulant effects of Rivaroxaban could be clinically useful. Methods for measuring Rivaroxaban concentrations are not available at all medical laboratories while the test MRX PT DOAC for ...
Liselotte Onelöv   +3 more
doaj   +1 more source

Serum Sortilin Levels as a Biomarker for Metabolic and Hormonal Dysregulation in Polycystic Ovary Syndrome

open access: yes
Background/Objectives: Polycystic ovarian syndrome (PCOS) is a complex endocrine disorder affecting up to 15% of reproductive-age women, characterized by hyperandrogenism, chronic oligo-ovulation, and metabolic dysfunction.
Mehmet Doruk, Pinar Alarslan
core   +1 more source

Systemic dysregulation of apolipoproteins in amyotrophic lateral sclerosis serum

open access: yesFEBS Open Bio, EarlyView.
Amyotrophic lateral sclerosis (ALS) is a fatal disease that damages motor neurons. This study found that people with ALS show significant changes in blood fats and the proteins that carry them. Several apolipoproteins were higher, lipid balances were altered, and normal protein–lipid relationships were disrupted.
Finula I. Isik   +6 more
wiley   +1 more source

Suppression of lung adenocarcinoma migration through organelle alkalization by human lactoferrin – albumin fusion

open access: yesFEBS Open Bio, EarlyView.
This paper reveals how human lactoferrin–albumin fusion (hLF‐HSA) potently suppresses lung adenocarcinoma cell migration. hLF‐HSA upregulates NHE7, leading to Golgi alkalization, disruption of the Golgi secretome, downregulation of MMP1, and reversal of EMT. These findings suggest a novel Golgi‐targeting strategy to suppress cancer cell migration.
Hana Nopia   +3 more
wiley   +1 more source

Alocação de energia celular de Chironomus riparius sob stress tóxico

open access: yes, 2010
Mestrado em Biologia AplicadaA alocação de energia celular (CEA) é um biomarcador energético que integra a análise das reservas energéticas disponíveis (conteúdo total de proteínas, lípidos e carbohidratos) e da energia consumida pelo organismo ...
Santos, Sílvia Camila Vasconcelos dos
core  

Identifying gene expression signatures for risk stratification of postoperative adjuvant chemotherapy in colorectal cancer

open access: yesFEBS Open Bio, EarlyView.
A novel signature integrating genome‐wide analysis with clinical factors predicts recurrence in stage II colorectal cancer and enables a new risk stratification to guide postoperative adjuvant chemotherapy. Clinical risk stratification for postoperative recurrence in patients with pathological stage II (pStage II) colorectal cancer (CRC) is essential ...
Mayuko Otomo   +7 more
wiley   +1 more source

Biomarker-Guided Anti-inflammatory Therapies: From Promise to Reality Check

open access: yes, 2019
Novel therapy development in psychiatry is at an impasse, with a significant lull since the 1980s and 1990s when most of the monoamine-targeted therapies that form the foundation of modern practice were first launched.
Adam Walker (13056642)   +2 more
core  

Home - About - Disclaimer - Privacy